FDAapproval65% confidence
FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors
Source: FDA
Why This Matters
Why this matters: provides agency context on approval that may shape timing or evidence expectations for Roche.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Oncology · KRAS Inhibitor
- Sub-indication
- General
Related signal: Phase I/II Study of GDC-7035 in Advanced Solid Tumors with KRAS G12D Mutation